SYN-020 Licensed to Rasayana Therapeutics, Advancing Oncology Drug Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy TOVX?
"We are very pleased to have completed the licensing of our versatile Phase 2-ready asset SYN-020 to Rasayana Therapeutics, executing on our plan to derive value from our GI portfolio while we remain focused on the advancement of our oncology pipeline," said Steven A. Shallcross, CEO. "We continue to advance our lead oncolytic virus candidate VCN-01 towards pivotal clinical development in multiple indications of high unmet need. With the recent feedback from the EMA, we have further clarity on dosing regimen, protocol and overall design for our proposed Phase 3 trial in pancreatic ductal adenocarcinoma. An End-of-Phase 2 meeting with the FDA is planned for the first half of 2026 to finalize our design for a multinational pivotal Phase 3 trial in PDAC, aiming to provide patients with a novel therapy for this difficult to treat solid tumor that has a high mortality rate. Additional interactions with the FDA and EMA are planned for 2026 to refine the design of a potential Phase 2/3 trial for retinoblastoma, for which VCN-01 has received Orphan Drug and Rare Pediatric Disease designation. We continue to engage in potential partnership discussions for the additional innovative drug candidates in our portfolio."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TOVX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TOVX
About TOVX
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Theriva Biologics Reports FY GAAP EPS of -$2.08
- Financial Performance: Theriva Biologics reported a fiscal year GAAP EPS of -$2.08, indicating challenges in profitability that could impact investor confidence and future fundraising capabilities.
- Cash Flow Status: As of December 31, 2025, the company's cash and cash equivalents totaled $13.1 million, an increase from $11.6 million in 2024, suggesting some improvement in liquidity.
- Recent Cash Position: As of February 26, 2026, Theriva Biologics had approximately $15.2 million in cash, indicating a short-term improvement in funding that may support ongoing operations.
- Market Reaction Outlook: Despite the cash flow improvement, the continued negative earnings may raise concerns about the company's future growth potential, affecting stock performance and investor confidence.
See More
Small-Cap Acquisitions Drive Market Gains
- Acquisition Surge: Interactive Strength (NASDAQ:TRNR) announced a definitive agreement to acquire Ergatta, which is expected to boost 2026 revenue guidance by 50% to over $30 million, with Ergatta alone projected to contribute more than $10 million in revenue, enhancing TRNR's competitive edge in the fitness market.
- Cash Flow Growth: The transaction caps the maximum enterprise value at $19.5 million based on an EBITDA of approximately $4 million for 2026, and is expected to be immediately accretive to TRNR's earnings, driving market share expansion in the fitness industry.
- Production Program Launch: Kraig Biocraft Laboratories (OTCQB:KBLB) confirmed the activation of its 2026 production program, with bio-materials moved to incubation, marking its leadership in scalable spider silk manufacturing and accelerating commercialization in defense and medical applications.
- Patent Expansion: NorthStrive Biosciences filed 10 new U.S. patent applications targeting animal health and agriculture, aiming to enhance muscle growth and reduce environmental impact, further solidifying the company's position at the intersection of sustainable farming and biopharma innovation.
See More
Etsy Sells Depop to eBay for $1.2 Billion
- Significant Transaction Value: Etsy has entered into a definitive agreement with eBay to sell its fashion marketplace Depop for approximately $1.2 billion in cash, which not only provides Etsy with substantial cash flow but also enhances its financial flexibility to support future strategic investments.
- Stock Price Surge: Etsy's shares jumped 15.5% to $50.86 in pre-market trading, reflecting a positive market reaction to the deal and increasing investor confidence in the company's future growth potential.
- Market Consolidation Trend: This transaction signifies further consolidation in the e-commerce sector, as eBay's acquisition of Depop will expand its influence in the fashion market, while Etsy can focus on its core business to improve operational efficiency.
- Strategic Focus Shift: By selling Depop, Etsy can reallocate resources to concentrate on growth within its primary platform, with expectations to drive long-term profitability through optimizing product lines and enhancing user experience.
See More
Theriva Biologics Receives EMA Support for Phase 3 Trial of VCN-01
- Strong Stock Performance: Theriva Biologics' stock rose 4.03% on Monday with a trading volume of 114.18 million shares, significantly exceeding the average volume of 15.61 million shares, indicating positive market sentiment regarding its clinical advancements.
- Clinical Trial Design Approved: The company received Scientific Advice from the EMA's Committee for Medicinal Products for Human Use, supporting its Phase 3 trial design for VCN-01, aimed at evaluating its efficacy in combination with standard chemotherapy, potentially offering new treatment options for pancreatic cancer patients.
- Survival Rate Improvement: In the previous VIRAGE Phase 2 trial, patients treated with VCN-01 in combination with standard chemotherapy demonstrated higher overall survival and progression-free survival rates, particularly those receiving two doses of VCN-01, further validating the drug's potential efficacy.
- Healthy Cash Position: As of November 10, 2025, Theriva had $15.5 million in cash and equivalents, providing a runway into the first quarter of 2027, facilitating interactions with regulatory agencies and scaling up VCN-01 manufacturing.
See More
Theriva Receives EMA Approval for Phase 3 Trial of VCN-01 in Metastatic PDAC
- Trial Design Approval: Theriva has received EMA approval for the Phase 3 trial design of VCN-01 in combination with gemcitabine/nab-paclitaxel for metastatic PDAC, which is expected to significantly enhance patient survival and treatment outcomes.
- Funding Runway Until 2027: Theriva's cash reserves are projected to last until Q1 2027, ensuring the company can complete regulatory activities and trial designs, thereby strengthening its competitive position in cancer treatment.
- FDA Meeting Scheduled: Theriva plans to hold an End-of-Phase 2 meeting with the FDA in H1 2026 to finalize the design of the Phase 3 trial, further advancing VCN-01's path to market.
- Potential of Multi-Dose Regimen: EMA acknowledged the significant survival improvement in patients receiving two doses of VCN-01 in the VIRAGE study, and Theriva plans to explore the application of three or more doses in the Phase 3 trial to achieve even better therapeutic outcomes.
See More
Theriva Receives EMA Approval for Phase 3 Trial of VCN-01 in Metastatic PDAC
- Trial Design Approval: Theriva has received scientific advice from the EMA regarding the Phase 3 trial design for VCN-01 in combination with gemcitabine/nab-paclitaxel for metastatic PDAC, marking a significant advancement in cancer treatment.
- Survival Rate Improvement: The VIRAGE Phase 2 trial demonstrated that patients receiving two doses of VCN-01 exhibited higher overall survival and progression-free survival, indicating the drug's potential in treating metastatic pancreatic cancer.
- Financial Support: Theriva anticipates having $15.5 million in cash reserves until Q1 2027, which will support regulatory activities and clinical trial execution, ensuring financial stability during critical phases.
- Future Planning: The company plans to hold an End-of-Phase 2 meeting with the FDA in H1 2026 to finalize the design of the Phase 3 trial, aiming to provide innovative treatment options for patients and further enhance its strategic positioning in cancer therapy.
See More
Theriva Biologics Reports FY GAAP EPS of -$2.08
- Financial Performance: Theriva Biologics reported a fiscal year GAAP EPS of -$2.08, indicating challenges in profitability that could impact investor confidence and future fundraising capabilities.
- Cash Flow Status: As of December 31, 2025, the company's cash and cash equivalents totaled $13.1 million, an increase from $11.6 million in 2024, suggesting some improvement in liquidity.
- Recent Cash Position: As of February 26, 2026, Theriva Biologics had approximately $15.2 million in cash, indicating a short-term improvement in funding that may support ongoing operations.
- Market Reaction Outlook: Despite the cash flow improvement, the continued negative earnings may raise concerns about the company's future growth potential, affecting stock performance and investor confidence.
See More
Small-Cap Acquisitions Drive Market Gains
- Acquisition Surge: Interactive Strength (NASDAQ:TRNR) announced a definitive agreement to acquire Ergatta, which is expected to boost 2026 revenue guidance by 50% to over $30 million, with Ergatta alone projected to contribute more than $10 million in revenue, enhancing TRNR's competitive edge in the fitness market.
- Cash Flow Growth: The transaction caps the maximum enterprise value at $19.5 million based on an EBITDA of approximately $4 million for 2026, and is expected to be immediately accretive to TRNR's earnings, driving market share expansion in the fitness industry.
- Production Program Launch: Kraig Biocraft Laboratories (OTCQB:KBLB) confirmed the activation of its 2026 production program, with bio-materials moved to incubation, marking its leadership in scalable spider silk manufacturing and accelerating commercialization in defense and medical applications.
- Patent Expansion: NorthStrive Biosciences filed 10 new U.S. patent applications targeting animal health and agriculture, aiming to enhance muscle growth and reduce environmental impact, further solidifying the company's position at the intersection of sustainable farming and biopharma innovation.
See More
Etsy Sells Depop to eBay for $1.2 Billion
- Significant Transaction Value: Etsy has entered into a definitive agreement with eBay to sell its fashion marketplace Depop for approximately $1.2 billion in cash, which not only provides Etsy with substantial cash flow but also enhances its financial flexibility to support future strategic investments.
- Stock Price Surge: Etsy's shares jumped 15.5% to $50.86 in pre-market trading, reflecting a positive market reaction to the deal and increasing investor confidence in the company's future growth potential.
- Market Consolidation Trend: This transaction signifies further consolidation in the e-commerce sector, as eBay's acquisition of Depop will expand its influence in the fashion market, while Etsy can focus on its core business to improve operational efficiency.
- Strategic Focus Shift: By selling Depop, Etsy can reallocate resources to concentrate on growth within its primary platform, with expectations to drive long-term profitability through optimizing product lines and enhancing user experience.
See More
Theriva Biologics Receives EMA Support for Phase 3 Trial of VCN-01
- Strong Stock Performance: Theriva Biologics' stock rose 4.03% on Monday with a trading volume of 114.18 million shares, significantly exceeding the average volume of 15.61 million shares, indicating positive market sentiment regarding its clinical advancements.
- Clinical Trial Design Approved: The company received Scientific Advice from the EMA's Committee for Medicinal Products for Human Use, supporting its Phase 3 trial design for VCN-01, aimed at evaluating its efficacy in combination with standard chemotherapy, potentially offering new treatment options for pancreatic cancer patients.
- Survival Rate Improvement: In the previous VIRAGE Phase 2 trial, patients treated with VCN-01 in combination with standard chemotherapy demonstrated higher overall survival and progression-free survival rates, particularly those receiving two doses of VCN-01, further validating the drug's potential efficacy.
- Healthy Cash Position: As of November 10, 2025, Theriva had $15.5 million in cash and equivalents, providing a runway into the first quarter of 2027, facilitating interactions with regulatory agencies and scaling up VCN-01 manufacturing.
See More
Theriva Receives EMA Approval for Phase 3 Trial of VCN-01 in Metastatic PDAC
- Trial Design Approval: Theriva has received EMA approval for the Phase 3 trial design of VCN-01 in combination with gemcitabine/nab-paclitaxel for metastatic PDAC, which is expected to significantly enhance patient survival and treatment outcomes.
- Funding Runway Until 2027: Theriva's cash reserves are projected to last until Q1 2027, ensuring the company can complete regulatory activities and trial designs, thereby strengthening its competitive position in cancer treatment.
- FDA Meeting Scheduled: Theriva plans to hold an End-of-Phase 2 meeting with the FDA in H1 2026 to finalize the design of the Phase 3 trial, further advancing VCN-01's path to market.
- Potential of Multi-Dose Regimen: EMA acknowledged the significant survival improvement in patients receiving two doses of VCN-01 in the VIRAGE study, and Theriva plans to explore the application of three or more doses in the Phase 3 trial to achieve even better therapeutic outcomes.
See More
Theriva Receives EMA Approval for Phase 3 Trial of VCN-01 in Metastatic PDAC
- Trial Design Approval: Theriva has received scientific advice from the EMA regarding the Phase 3 trial design for VCN-01 in combination with gemcitabine/nab-paclitaxel for metastatic PDAC, marking a significant advancement in cancer treatment.
- Survival Rate Improvement: The VIRAGE Phase 2 trial demonstrated that patients receiving two doses of VCN-01 exhibited higher overall survival and progression-free survival, indicating the drug's potential in treating metastatic pancreatic cancer.
- Financial Support: Theriva anticipates having $15.5 million in cash reserves until Q1 2027, which will support regulatory activities and clinical trial execution, ensuring financial stability during critical phases.
- Future Planning: The company plans to hold an End-of-Phase 2 meeting with the FDA in H1 2026 to finalize the design of the Phase 3 trial, aiming to provide innovative treatment options for patients and further enhance its strategic positioning in cancer therapy.
See More
